Datum | Källa | Rubrik | Typ | Alternativ | ||||||
---|---|---|---|---|---|---|---|---|---|---|
2024-05-17 | Spago Nanomedical | The exercise period for Spago Nanomedical's warrants of series TO12 commences today | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2024-05-17 | Spago Nanomedical | Nyttjandeperioden för Spago Nanomedicals teckningsoptioner av serie TO12 inleds idag | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2024-05-16 | Spago Nanomedical | Spago Nanomedical publishes the annual report for 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2024-05-16 | Spago Nanomedical | Spago Nanomedical publicerar årsredovisningen för 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2024-05-07 | Spago | BioStock: Spago's CEO - "Advancing the Tumorad programme comes first" | Pressreleaser | Visa Stäng | ||||||
|
||||||||||
2024-05-06 | Spago Nanomedical | KALLELSE TILL ÅRSSTÄMMA I SPAGO NANOMEDICAL AB (PUBL) | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2024-05-06 | Spago Nanomedical | NOTICE TO ANNUAL GENERAL MEETING OF SPAGO NANOMEDICAL AB (PUBL) | Pressreleaser | Ladda ner | Visa Stäng | ||||||
Pressreleaser |
NOTICE TO ANNUAL GENERAL MEETING OF SPAGO NANOMEDICAL AB (PUBL)This English version of the notice to the annual general meeting is for convenience only. The Swedish version prevails in the event of any inconsistency. The shareholders of Spago Nanomedical AB (publ), corporate registration number 556574-5048 are hereby summoned to the Annual General Meeting on Monday 10 June 2024, at 4.00 p.m. CEST at Advokatfirman Cederquist’s premises, Hovslagargatan 3, in Stockholm. Registration starts at 3.30 p.m. CEST. The board of directors has, in accordance with Spago Nanomedical’s articles of association, decided that the shareholders may also exercise their voting rights by postal voting prior to the general meeting. Right to attend and notice shall be registered in the share register kept by Euroclear Sweden AB concerning the circumstances on Thursday 30 May 2024,
When giving notice of attendance, the shareholders shall state their name, address, daytime telephone number and personal identification number or company registration number. Shareholders who wish to use the possibility of postal voting shall do that in accordance with the instructions under the heading “Postal voting” below. Such postal voting does not require any further notice of attendance. Nominee-registered shares Proxy etc. Postal voting The completed and signed voting form must be received by Spago Nanomedical no later than Monday 3 June 2024. The completed and signed form shall be sent by post to Advokatfirman Cederquist, P.O. Box 1670, SE-111 96 Stockholm, Sweden, Att: Ursula Sörqvist (mark the envelope with “Spago Nanomedical AB (publ), AGM 2024”), or by e-mail to ursula.sorqvist@cederquist.se. If a shareholder postal votes by proxy, a power of attorney must be enclosed with the form. A proxy form is available at the company’s website, www.spagonanomedical.se. If the shareholder is a legal entity, a certificate of incorporation or a corresponding document must be enclosed with the form. The shareholder may not provide special instructions or conditions in the voting form. If so, the vote (i.e. the postal vote in its entirety) is invalid. Further instructions and conditions are included in the form for postal voting. Processing of personal data
Proposed resolutions Item 9. (b) Resolution on dispositions regarding the company´s earnings in accordance with the adopted balance sheet Item 10. Determination of the number of directors and deputy directors of the board Item 11. Determination of remuneration to the directors of the board and the auditors The nomination committee proposes that remuneration to the auditor shall be paid in accordance with approved invoices. Item 12. Election of directors and chairman of the board of directors Further information about the proposed directors is available on the company´s website, www.spagonanomedical.se. The nomination committee proposes that Hans Arwidsson is re-elected as chairman of the board of directors. Item 13. Election of auditor Item 14. Resolution on authorisation for the board of directors to resolve to issue new shares and/or warrants The board of directors is authorised to, on one or several occasions before the next Annual General Meeting, resolve to issue new shares and/or warrants. Such issues of new shares and/or warrants may be made with or without deviation from the shareholders’ preferential rights. By resolutions based on the authorisation, issues of shares and/or warrants without deviation from the shareholders’ preferential rights may be made up to, in total, as many shares as falls within the limits of the articles of association at the time of exercise of the authorisation. By resolutions based on the authorisation, issues of shares and/or warrants with deviation from the shareholders’ preferential rights may be made up to, in total, the number of shares corresponding to twenty (20) percent of the total number of outstanding shares in the company at the time of exercise of the authorisation the first time. The authorisation shall include the right to resolve on issues where payment is made in cash, by contribution in kind, or by way of set-off. A cash issue or issue by way of set-off that is made with deviation from the shareholders’ preferential rights shall be carried out on market terms. The purpose of the authorisation and the reasons for potential deviations from the shareholders’ preferential rights are that issues shall be able to be made in order to enable capital raisings if market conditions would be deemed appropriate and/or to broaden Spago Nanomedical’s ownership base by offering financial and industrial investors to invest in the company. Item 15. Resolutions on amendment of the articles of association
Item 16. Resolutions on (a) amendment of the articles of association and (b) reduction of the share capital for allocation to unrestricted shareholders’ equity Item 16 (a). Resolution on amendment of the articles of association § 4 Share capital Item 16 (b). Resolution on reduction of the share capital for allocation to unrestricted shareholders’ equity The reduction may not be implemented until permission has been obtained from the Swedish Companies Registration Office, or in disputed cases, from the district court. Other information Majority requirements Number of shares Shareholders’ right to receive information Documents Lund, May 2024 |
||||||||||
2024-05-03 | Redeye | Redeye: Spago Nanomedical update after Q1 - Timely progress | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2024-05-03 | Penser Access by Carnegie | Penser Access by Carnegie: Spago Nanomedical - Temperaturen stiger | Pressreleaser | Visa Stäng | ||||||
|
||||||||||
2024-05-02 | Spago Nanomedical | Spago Nanomedical delårsrapport januari-mars 2024 | Rapporter | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2024-05-02 | Spago Nanomedical | Spago Nanomedical interim report January-March 2024 | Rapporter | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2024-04-24 | Spago Nanomedical | Spago Nanomedical rapporterar gynnsamma data i bröstcancermodell med Tumorad | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2024-04-24 | Spago Nanomedical | Spago Nanomedical reports favorable data in breast cancer model with Tumorad | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2024-04-16 | Spago Nanomedical | Spago Nanomedical strengthens management with Head of CMC & Supply | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2024-04-16 | Spago Nanomedical | Spago Nanomedical stärker ledningen med chef för CMC & Supply | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2024-03-28 | Penser Access by Carnegie | Penser Access by Carnegie: Intervju med Spago Nanomedical - Carnegie Investment Bank - 28 mar 2024 | Pressreleaser | Visa Stäng | ||||||
|
||||||||||
2024-03-27 | Spago | BioStock: Spago Nanomedical's CEO: "huge commercial opportunities are unfolding" | Pressreleaser | Visa Stäng | ||||||
|
||||||||||
2024-02-09 | Spago | BioStock: 2023 springboard for Spago's radionuclide cancer therapy | Pressreleaser | Visa Stäng | ||||||
|
||||||||||
2024-02-08 | Penser Access by Carnegie | Penser Access by Carnegie: Spago Nanomedical - Lockande nyhetsagenda | Pressreleaser | Visa Stäng | ||||||
|
||||||||||
2024-02-08 | Redeye | Redeye: Spago Nanomedical Q4 Update | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2024-02-07 | Spago Nanomedical | Spago Nanomedical bokslutskommuniké januari-december 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2024-02-07 | Spago Nanomedical | Spago Nanomedical year-end report January-December, 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2024-01-25 | Spago Nanomedical | The rights issue and the directed share issue to certain guarantors in Spago Nanomedical fully registered | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2024-01-25 | Spago Nanomedical | Företrädesemissionen och den riktade emissionen till vissa garanter i Spago Nanomedical slutregistrerade | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2024-01-18 | Spago Nanomedical | Spago Nanomedical presents at Redeye’s Fight Cancer event on January 24 | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2024-01-18 | Spago Nanomedical | Spago Nanomedical presenterar på Redeyes temadag Fight Cancer den 24 januari | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2024-01-15 | Spago | BioStock: Spago's phase I/IIa cancer trial progressing steadily | Pressreleaser | Visa Stäng | ||||||
|
||||||||||
2024-01-10 | Spago Nanomedical | Spago Nanomedical proceeds to the next dose level in the phase I/IIa study Tumorad-01 | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2024-01-10 | Spago Nanomedical | Spago Nanomedical går vidare till nästa dosnivå i fas I/IIa-studien Tumorad-01 | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2024-01-03 | Redeye | Redeye: Spago Nanomedical - Update after funding and initiation of Tumorad | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-12-20 | Spago | BioStock: Positive data in Spago's phase IIa endometriosis trial | Pressreleaser | Visa Stäng | ||||||
|
||||||||||
2023-12-18 | Penser Access by Carnegie | Penser Access by Carnegie: Spago Nanomedical - Uppmuntrande resultat | Pressreleaser | Visa Stäng | ||||||
|
||||||||||
2023-12-15 | Spago Nanomedical | Spago Nanomedical rapporterar positiva topline-data från den kliniska fas 2a studien SPAGOPIX-02 i patienter med endometrios | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-12-15 | Spago Nanomedical | Spago Nanomedical reports positive top line data from clinical phase IIa study SPAGOPIX-02 in patients with endometriosis | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-12-14 | Penser Access by Carnegie | Penser Access by Carnegie: Intervju med Spago Nanomedical - Carnegie Investment Bank - 14 dec 2023 | Pressreleaser | Visa Stäng | ||||||
|
||||||||||
2023-12-14 | Spago | BioStock: First patient dosed in Spago's phase I/IIa trial | Pressreleaser | Visa Stäng | ||||||
|
||||||||||
2023-12-13 | Spago Nanomedical | Spago Nanomedical carries out a directed issue of shares to guarantors following the completed rights issue | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-12-13 | Spago Nanomedical | Spago Nanomedical genomför riktad nyemission av aktier till garanter efter den genomförda företrädesemissionen | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-12-12 | Spago Nanomedical | Företrädesemissionen i Spago Nanomedical delregistrerad | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-12-12 | Spago Nanomedical | Rights issue in Spago Nanomedical partially registered | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-12-07 | Spago Nanomedical | Första patienten doserad i Spago Nanomedicals kliniska fas I/IIa-studie inom Tumorad®-programmet | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-12-07 | Spago Nanomedical | First patient dosed in Spago Nanomedical's clinical phase I/IIa study within the Tumorad® program | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-11-27 | Spago Nanomedical | Spago Nanomedical announces outcome of the rights issue | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-11-27 | Spago Nanomedical | Spago Nanomedical offentliggör utfall i företrädesemissionen | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-11-23 | Spago Nanomedical | Last day of the subscription period in Spago Nanomedical’s rights issue | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-11-23 | Spago Nanomedical | Sista dagen i teckningsperioden i Spago Nanomedicals företrädesemission | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-11-14 | Spago Nanomedical | Valberedning utsedd inför Spago Nanomedicals årsstämma 2024 | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-11-14 | Spago Nanomedical | Nomination committee appointed for Spago Nanomedical’s Annual General Meeting 2024 | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-11-09 | Spago Nanomedical | Idag börjar teckningsperioden i Spago Nanomedicals företrädesemission | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-11-09 | Spago Nanomedical | The subscription period in Spago Nanomedical’s rights issue begins today | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-11-08 | Penser Access | Penser Access: Betydelsefullt stöd från huvudägare - Spago Nanomedical | Pressreleaser | Visa Stäng | ||||||
|
||||||||||
2023-11-07 | Spago Nanomedical | Spago Nanomedical offentliggör prospekt med anledning av förestående företrädesemission | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-11-07 | Spago Nanomedical | Spago Nanomedical publishes prospectus in connection with forthcoming rights issue | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-11-03 | Spago Nanomedical | Spago Nanomedical delårsrapport januari-september 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-11-03 | Spago Nanomedical | Spago Nanomedical interim report January-September 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-10-31 | Spago Nanomedical | Bulletin from the Extraordinary General Meeting of Spago Nanomedical AB on 31 October 2023 | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-10-31 | Spago Nanomedical | Kommuniké från extra bolagsstämma i Spago Nanomedical AB den 31 oktober 2023 | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-10-30 | Spago | Spago: BioStock: Tumorad's potential in transforming cancer care | Pressreleaser | Visa Stäng | ||||||
|
||||||||||
2023-10-30 | Spago | Spago: BioStock: Tumorad's potential in transforming cancer care | Pressreleaser | Visa Stäng | ||||||
|
||||||||||
2023-10-24 | Spago Nanomedical | Spago Nanomedical ansöker om utökat patentskydd för Tumorad® | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-10-24 | Spago Nanomedical | Spago Nanomedical applies for extended patent protection for Tumorad® | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-10-23 | Spago | BioStock: Spago Nanomedical's promising cancer therapy approved for phase I/IIa | Pressreleaser | Visa Stäng | ||||||
|
||||||||||
2023-10-19 | Spago Nanomedical | Spago Nanomedical receives approval to initiate the clinical phase I/IIa study with Tumorad® in Australia | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-10-19 | Spago Nanomedical | Spago Nanomedical får klartecken att starta klinisk fas I/IIa-studie med Tumorad® i Australien | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-10-18 | Spago | Spago Nanomedical presenterar på BioStock Life Science Summit den 25 oktober | Pressreleaser | Visa Stäng | ||||||
|
||||||||||
2023-10-11 | Penser Access | Penser Access: Intervju med Spago Nanomedical - Erik Penser Bank - 11 oktober 2023 | Pressreleaser | Visa Stäng | ||||||
|
||||||||||
2023-10-05 | Spago Nanomedical | Kallelse till extra bolagsstämma i Spago Nanomedical AB (publ) | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-10-05 | Spago Nanomedical | Notice to the Extraordinary General Meeting of Spago Nanomedical AB (publ) | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-10-05 | Spago Nanomedical | Spago Nanomedical proposes a fully guaranteed rights issue of units of approximately SEK 30.6 million to advance Tumorad | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-10-05 | Spago Nanomedical | Spago Nanomedical föreslår en fullt garanterad företrädesemission av units om cirka 30,6 MSEK för att avancera Tumorad | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-08-14 | Penser Access | Penser Access: Sticker ut i mängden - Spago Nanomedical | Pressreleaser | Visa Stäng | ||||||
|
||||||||||
2023-08-01 | Redeye | Redeye: Spago Nanomedical Q2 - Milestone almost concluded, continued cost control crucial | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-07-31 | Spago Nanomedical | Spago Nanomedical delårsrapport januari-juni 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-07-31 | Spago Nanomedical | Spago Nanomedical interim report January-June 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-06-29 | Spago | BioStock: Spago Nanomedical's SAB on Tumorad's potential | Pressreleaser | Visa Stäng | ||||||
|
||||||||||
2023-06-28 | Spago Nanomedical | Spago Nanomedical updates on the clinical phase IIa study SPAGOPIX-02 | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-06-28 | Spago Nanomedical | Spago Nanomedical uppdaterar om den kliniska fas IIa-studien SPAGOPIX-02 | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-06-13 | Spago Nanomedical | Spago Nanomedical stärker Tumorad® genom nytt vetenskapligt råd | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-06-13 | Spago Nanomedical | Spago Nanomedical strengthens Tumorad® by establishment of Scientific Advisory Board | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-05-30 | Spago | BioStock: Spago Nanomedical's CDO on study submission | Pressreleaser | Visa Stäng | ||||||
|
||||||||||
2023-05-30 | Spago | BioStock: Spago Nanomedicals CDO om studieansökan | Pressreleaser | Visa Stäng | ||||||
|
||||||||||
2023-05-23 | Spago Nanomedical | Spago Nanomedical has submitted application to start Tumorad® clinical phase I/IIa study | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|
||||||||||
2023-05-23 | Spago Nanomedical | Spago Nanomedical har lämnat in ansökan om att starta klinisk fas I/IIa-studie med Tumorad® | Pressreleaser | Ladda ner | Visa Stäng | ||||||
|